|
|
| |
| The sense that quietly guards your memory |
| Start with your ears. A large Lancet review keeps hearing loss near the top of the dementia risks you can actually change. It sits above most things people worry about. |
| New numbers back the case. A 2026 report in the journal Neurology followed 2,777 older adults; 664 were fitted with hearing aids. Among the aid users, 5 in 100 went on to develop dementia. Among those who went without, it was 8 in 100. That works out to about a third lower risk. And the more steadily people wore the aids, the lower the risk ran. |
| That is a big drop for a fix this ordinary. |
| Let me explain what fading hearing does to a brain. When sound turns muddy, the brain strains to fill the gaps, and every talk becomes hard work. That effort is stolen from memory and thinking. Quiet also pulls people out of the room — they call less, go out less. And a brain with less sound and less company slowly shrinks in the very spots that hold memory. Picture a radio tuned just off the station. You can still follow it, but you burn all your focus on the static. |
| |
The honest catch is worth saying plainly. The aids did not raise anyone’s memory-test score. They lowered who went on to dementia. Those are not the same thing, and the study is careful about it. |
|
| I could be wrong on how much of this is cause. This is a link, not a clean trial, and healthier people may reach for aids sooner. But the direction keeps turning up, study after study. And the fix carries almost no risk, unlike most things in this field. I believe treated hearing is one of the surest bets you have. |
| So I urge you, plainly. Get a hearing test this year, the way you check blood pressure. If sounds have gone dull, act on it. Your brain is doing the listening — give it a clean signal. |
| Neurology · February 2026 · and the Lancet review of dementia risk |
|
|
|
|
| |
| Two minutes to take the edge off |
| Your breath has a brake pedal. Slow, long exhales tell the body to stand down. The heart eases. The mind quiets. And a calm body thinks more clearly than a wired one. |
| A Stanford team tested this in plain terms. In a 2023 report in Cell Reports Medicine, people did five minutes of breathing a day for a month. One method won: the cyclic sigh. Two breaths in through the nose, then a long breath out through the mouth. It beat sitting meditation on mood. It also slowed the breath more than the rest. Think of it as letting the air out of an over-pumped tire, slowly and on purpose. |
| You do not need an app or a cushion. |
| The Protocol |
| When |
| A keyed-up moment — or once a day, on purpose |
| Duration |
| Five minutes, or even one when time is short |
| Rules |
| Two breaths in through the nose, topping up on the second sip. Then a long, slow breath out through the mouth until the lungs feel empty. Repeat, and let the exhale be the longest part. Sit or stand, eyes open or closed. |
| |
| Watch the ten minutes after you finish — that is where the shoulders drop. I urge you to try it before your next hard phone call. |
|
|
|
|
|
|
|
| You may be choosing on autopilot |
| Watch for a quiet trap. Researchers at TU Dresden had more than 700 people make choices, again and again. The more often someone repeated a pick, the more they came to like it. That held even when a better option sat right there. The act of choosing shaped the preference, not the other way around. So on the choices that matter, stop and look again as if it were the first time. |
| Communications Psychology · 2026 |
|
|
| Your coffee may be pulling its weight |
| Your morning cup earns its keep. A 2026 study in JAMA followed more than 130,000 health workers for decades. Those who drank two to three cups a day — about 250 to 300 milligrams of caffeine — had roughly a third less dementia by their mid-70s. More than that added nothing. The sugar and cream are still their own problem. And this is a link, not a green light, so skip it if coffee wrecks your sleep. |
| JAMA · May 2026 |
|
|
| Loud snoring is worth a real look |
| Snoring can hide a bigger problem. In sleep apnea, the airway keeps closing at night, so the brain’s oxygen dips again and again. Work from the University of Miami followed more than 3,000 adults. It ties apnea to weaker memory, a smaller memory center, and worn small vessels. The fix is real. Treating it, often with an air machine at night, can protect the brain. If you snore hard or wake up gasping, ask for a sleep test. |
| University of Miami · 2026 |
|
|
|
|
| |
| The Alzheimer’s pipeline is not one road. Some drugs chase the plaques. One goes after the tangles. And one big miss this year taught the field as much as a win. Here are three worth watching. |
|
| Sneaks the cleanup drug past the brain’s gate |
| Most Alzheimer’s antibodies barely reach the brain, because the blood-brain barrier keeps big drugs out. Roche’s trontinemab hitches a ride on the brain’s iron-delivery system to slip through. In early trials, 9 in 10 people cleared their amyloid plaques within about seven months. The doses were low, and brain swelling was rare. Amyloid plaques are the sticky protein buildup tied to the disease. |
| Roche · Phase 3 (TRONTIER) · from 2025 |
|
|
| Goes after the tangles, not the plaques |
| Amyloid is only half the story. Tau is the protein that knots into tangles inside brain cells and spreads as symptoms worsen. Bepranemab, from UCB and Roche, is an antibody aimed at tau. In a mid-stage trial called TOGETHER, it slowed the buildup of tau on brain scans. Whether that turns into clearer thinking is the next question. |
| UCB / Roche · Phase 2 (TOGETHER) |
|
|
| The Ozempic-type drug that missed, and still taught us |
| This one is a miss, told straight. Semaglutide is the blood-sugar and weight drug sold as Ozempic. It was tested in early Alzheimer’s in a large trial called EVOKE. Over two years, it did not slow the disease against a dummy pill. The lesson researchers drew is about timing. Once Alzheimer’s has set in, steadying blood sugar may come too late. The window to protect the brain is earlier — which is the whole point of the habits in this issue. |
| Novo Nordisk · Phase 3 (EVOKE) · full data 2026 |
|
|
